Not for release, distribution or publication, in whole or in part, directly or indirectly, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where the release, distribution or publication of this press release would be unlawful or require additional registration or other measures. For further information, please see the section “Important information” at the end of this press release.

The information in this press release is intended for investors.

Isofol has received a top guarantee commitment for the exercise of warrants of series TO2

GOTHENBURG, Sweden, November 27, 2026 – Isofol Medical AB ("Isofol" or the "Company") announces that the Company has received a top guarantee commitment totalling SEK 16.5 million, corresponding to approximately 44 per cent of the proceeds from the full exercise of the warrants of series TO2. The Company carried out a rights issue of units in June/July 2025. In connection with the rights issue, Isofol issued a total of 39,863,928 warrants of series TO2. The exercise period for the warrants of series TO2 runs from 16 November 2026 up to and including 30 November 2026. Together with the subscription commitments from major shareholders, Board members and management of approximately SEK 5.8 million announced on 24 November 2026, and Solasia Pharma K.K.'s stated intention to exercise all of its warrants of series TO2 of approximately SEK 2.0 million, the exercise of the warrants of series TO2 is thereby covered by subscription commitments, a statement of intent and a top guarantee totalling approximately SEK 24.3 million, corresponding to approximately 64 per cent of the proceeds upon full exercise of the warrants of series TO2.

Top guarantee commitment

The Company has entered into a top guarantee agreement with ABG Sundal Collier ASA (the "Guarantor"). Under the top guarantee, the Guarantor has undertaken to guarantee SEK 16.5 million, corresponding to approximately 44 per cent of the proceeds that the Company may receive upon full exercise of the warrants of series TO2. The top guarantee will lapse if the warrants of series TO2 are exercised in full. If the top guarantee is called upon, in whole or in part, the Guarantor will subscribe for shares in a directed share issue in the Company at a subscription price corresponding to the fixed exercise price of the warrants of series TO2, SEK 0.95 per share.

If the Guarantor's top guarantee is called upon, Isofol's Board of Directors intends to exercise the authorisation granted by the Annual General Meeting on 19 May 2026 and resolve on a directed share issue on the same terms as those applicable to the exercise of TO2. The top guarantee commitment has been provided in return for a cash fee of nine (9) per cent of the guaranteed amount. The guarantee commitment has been agreed in writing but has not been secured by a bank guarantee, blocked funds, a pledge or similar arrangements, and there is therefore a risk that the guarantee commitment will not be fulfilled.

Advisors

ABG Sundal Collier AB is acting as financial adviser to the Company, Advokatfirman Vinge KB as legal adviser to the Company and Aqurat Fondkommission as issuing agent in connection with the administration of TO2.

Not for release, distribution or publication, in whole or in part, directly or indirectly, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where the release, distribution or publication of this press release would be unlawful or require additional registration or other measures. For further information, please see the section "Important information" at the end of this press release.

For further information, please contact

Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0)739 60 12 56

Margareta Hagman, Chief Financial Officer
E-mail: margareta.hagman@isofolmedical.com
Phone: +46 (0)738 73 34 18

The information was submitted for publication, through the agency of the contact persons listed above, on November 27, 2026 at 08:30 CET.

About Isofol

Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company's drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world's third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.

www.isofolmedical.com

Important information

The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Isofol. No action has been taken, nor will any action be taken, to permit an offer to the public in any jurisdiction other than Sweden.

This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. This press release neither identifies nor purports to identify the risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Isofol. In order for an investor to fully understand the potential risks and benefits associated with a decision to exercise warrants, any investment decision should be made solely on the basis of the information in the prospectus published by the Company on 17 June 2025 (the "**Prospectus**"). Investors are therefore recommended to read the Prospectus in its entirety. This press release constitutes an **advertisement** in accordance with Article 2(k) of the Prospectus Regulation.

The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require measures other than those required under Swedish law. Actions in violation of this instruction may constitute a breach of applicable securities legislation. No shares, warrants or other securities in Isofol have been or will be registered under the United States Securities Act of 1933, as amended (the "**Securities Act**"), or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with the securities laws of the relevant state or other jurisdiction of the United States.

Within the European Economic Area (the "**EEA**"), no offer of shares, warrants or other securities (the "**Securities**") is being made to the public in any country other than Sweden. In other Member States of the European Union (the "**EU**"), any such offer of Securities may only be made pursuant to exemptions under the Prospectus Regulation (EU) 2017/1129. In other EEA countries that have implemented the Prospectus Regulation in national law, any such offer of Securities may only be made pursuant to exemptions under the Prospectus Regulation and in accordance with any relevant implementing measures. In other EEA countries that have not implemented the Prospectus Regulation in national law, any such offer of Securities may only be made pursuant to an applicable exemption under national law.

In the United Kingdom, this document and any other materials relating to the securities referred to herein are distributed and directed only at, and any investment or investment activity to which this document relates is available only to and will be engaged in only with, "qualified investors" (within the meaning of the UK version of Regulation (EU) 2017/1129 which forms part of UK law by virtue of the European Union (Withdrawal) Act 2018)
who are (i) persons having professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); (ii) "high net worth entities" etc. referred to in Article 49(2)(a)–(d) of the Order; or (iii) other persons to whom such investment or investment activity may lawfully be directed under the Order (all such persons together being referred to as "**relevant persons**"). Any investment or investment activity to which this announcement relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action on the basis of this document or act or rely on it.

This press release may contain certain forward-looking information that reflects the Company's current views on future events and financial and operational developments. Words such as "*intends*", "*will*", "*assesses*", "*expects*", "*may*", "*plans*", "*believes*", "*estimates*" and other expressions indicating or predicting future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is by its nature associated with both known and unknown risks and uncertainties, as it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future results or developments, and actual outcomes may differ materially from those expressed in such forward-looking information.

The information, opinions and forward-looking statements contained in this press release apply only as of this date and are subject to change without notice. Isofol makes no undertaking to publish updates or revisions to forward-looking information, future events or similar circumstances other than as required by applicable law.

As Isofol conducts activities worthy of protection under the Swedish Screening of Foreign Direct Investments Act (2023:560), certain investments in the Company's shares may be subject to review by the Swedish Inspectorate of Strategic Products. Further information is available on the Company's website, www.isofolmedical.com.